Physician profile
Ellen B Hight
NPI 1548240971
$4,225.55
in general payments reported to CMS, 2019-2025
31 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $63.00 · 2021: $411 · 2022: $767 · 2023: $910 · 2024: $894 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $811.39 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $623.71 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $616.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $445.93 | 2019-2025 | |
| Amgen INC. | $248.48 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $213.39 | 2019-2024 | Trelegy Ellipta, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $123.05 | 2019-2024 | Gardasil 9, M-M-R II, Vaxelis |
| Lilly USA, LLC | $116.73 | 2019-2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company Ltd. | $104.14 | 2022 | |
| Antares Pharma, INC. | $82.70 | 2024-2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $81.92 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $72.88 | 2021-2023 | Gvoke Hypopen |
| Ucb, INC. | $65.36 | 2019-2025 | Bimzelx |
| Abbott Laboratories | $61.00 | 2022-2023 | Freestyle Libre 3 |
| Mayne Pharma Commercial LLC | $59.16 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $51.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.87 | 2019-2025 | Orencia |
| Exact Sciences Corporation | $44.31 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $43.71 | 2019-2021 | |
| Amarin Pharma, INC. | $40.29 | 2021-2022 | |
| Abiomed | $33.78 | 2024 | Impella |
| Axsome Therapeutics, INC. | $28.71 | 2025 | Auvelity |
| Corium, LLC | $28.02 | 2023 | Azstarys |
| Allergan, INC. | $26.89 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.00 | 2022 | |
| Dexcom, INC. | $24.52 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $23.60 | 2019 | |
| Bausch Health US, LLC | $22.65 | 2022 | |
| Astellas Pharma US INC | $21.89 | 2021 | |
| Coopersurgical, INC. | $17.86 | 2024 | Paragard T 380a |
| Regeneron Healthcare Solutions, INC. | $17.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Hight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.